CA2629402C - Modulateurs de beta-secretase et procedes d'utilisation associes - Google Patents
Modulateurs de beta-secretase et procedes d'utilisation associes Download PDFInfo
- Publication number
- CA2629402C CA2629402C CA2629402A CA2629402A CA2629402C CA 2629402 C CA2629402 C CA 2629402C CA 2629402 A CA2629402 A CA 2629402A CA 2629402 A CA2629402 A CA 2629402A CA 2629402 C CA2629402 C CA 2629402C
- Authority
- CA
- Canada
- Prior art keywords
- amino
- acetamide
- methyl
- dihydrospiro
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrane Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73910805P | 2005-11-21 | 2005-11-21 | |
US60/739,108 | 2005-11-21 | ||
US85482406P | 2006-10-27 | 2006-10-27 | |
US60/854,824 | 2006-10-27 | ||
PCT/US2006/044058 WO2007061670A1 (fr) | 2005-11-21 | 2006-11-13 | Modulateurs de beta-secretase et procedes d'utilisation associes |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2629402A1 CA2629402A1 (fr) | 2007-05-31 |
CA2629402C true CA2629402C (fr) | 2011-07-26 |
Family
ID=39708735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2629402A Expired - Fee Related CA2629402C (fr) | 2005-11-21 | 2006-11-13 | Modulateurs de beta-secretase et procedes d'utilisation associes |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1971598A1 (fr) |
JP (1) | JP5274258B2 (fr) |
AR (1) | AR057985A1 (fr) |
AU (1) | AU2006316620B2 (fr) |
CA (1) | CA2629402C (fr) |
PE (1) | PE20070645A1 (fr) |
TW (1) | TW200800966A (fr) |
WO (1) | WO2007061670A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
MX2009012608A (es) * | 2007-05-25 | 2009-12-07 | Amgen Inc | Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso. |
US8163909B2 (en) * | 2007-05-25 | 2012-04-24 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
EP2734494B1 (fr) | 2011-07-21 | 2019-01-02 | GE Healthcare Limited | Composés précurseurs et leurs procédés de fabrication |
CA2867851A1 (fr) * | 2012-03-20 | 2013-09-26 | Elan Pharmaceuticals, Inc. | Dihydro-thiazine spirocycliques et inhibiteurs de bace dihydro-oxazine et compositions et utilisations de ceux-ci |
JP6562361B2 (ja) * | 2014-07-16 | 2019-08-21 | 国立研究開発法人科学技術振興機構 | ベンゾチアゾール化合物及びこれを含有する医薬 |
US20220185815A1 (en) | 2019-03-06 | 2022-06-16 | Daiichi Sankyo Company, Limited | Pyrrolopyrazole derivative |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY138097A (en) | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
ATE314343T1 (de) | 2000-06-30 | 2006-01-15 | Elan Pharm Inc | Verbindungen zur behandlung der alzheimerischen krankheit |
US7196163B2 (en) | 2001-05-22 | 2007-03-27 | Merk & Co., Inc. | Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity |
US6982264B2 (en) | 2001-06-27 | 2006-01-03 | Elan Pharmaceuticals, Inc. | Substituted alcohols useful in treatment of Alzheimer's disease |
KR100713137B1 (ko) | 2001-06-28 | 2007-05-02 | 동화약품공업주식회사 | 신규의 2,4-디플루오로벤즈아미드 유도체 |
WO2003006013A1 (fr) | 2001-07-10 | 2003-01-23 | Elan Pharmaceuticals, Inc. | Diaminediols pour le traitement de la maladie d'alzheimer |
WO2003006021A1 (fr) | 2001-07-10 | 2003-01-23 | Elan Pharmaceuticals, Inc. | Derives de statine alpha-hydroxyamide pour le traitement de la maladie d'alzheimer |
PL368052A1 (en) | 2001-07-11 | 2005-03-21 | Elan Pharmaceuticals, Inc. | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
CA2462851A1 (fr) | 2001-10-04 | 2003-04-10 | Elan Pharmaceuticals, Inc. | Hydroxypropylamines |
BR0213138A (pt) | 2001-10-05 | 2004-08-24 | Elan Pharm Inc | Métodos de tratar ou prevenir mal de alzheimer e uma doença distinguida por depósito de beta-amilóide no cérebro, de tratar um paciente que tenha, ou de prevenir um paciente de contrair uma doença ou condição, de produzir um complexo de beta-secretase e de inibir a produção de placa beta-amilóide em um animal, composição e uso de um composto |
US20050038019A1 (en) | 2001-10-29 | 2005-02-17 | Beck James P. | Hydroxy substituted amides for the treatment of alzheimer's disease |
EA200400648A1 (ru) | 2001-11-08 | 2005-04-28 | Элан Фармасьютикалз, Инк. | N, n'-замещенные производные 1,3-диамино-2-гидроксипропана |
TW200304374A (en) | 2001-11-30 | 2003-10-01 | Smithkline Beecham Plc | Novel compounds |
BR0214736A (pt) | 2001-12-06 | 2004-11-23 | Elan Pharm Inc | Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica e método de tratar seres humanos ou animais que sofrem de doenças ou condições |
WO2003057721A2 (fr) | 2002-01-04 | 2003-07-17 | Elan Pharmaceuticals, Inc. | Amino carboxamides substitues destines au traitement de la maladie d'alzheimer |
EP1471910A2 (fr) | 2002-01-17 | 2004-11-03 | Neurogen Corporation | Analogues de quinazoline-4-ylamine substitues comme modulateurs de receptors de la capsaicin |
AU2003276047A1 (en) | 2002-06-17 | 2003-12-31 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
ATE370131T1 (de) | 2002-06-20 | 2007-09-15 | Pharmacia & Upjohn Co Llc | Verfahren zur herstellung von 5-(1,3-oxazol-2- yl)benzoesäurederivaten |
UY27967A1 (es) | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
US7362070B2 (en) | 2002-11-04 | 2008-04-22 | Hamilton Sundstrand Corporation | Electric motor control system including position determination and error correction |
WO2004043916A1 (fr) | 2002-11-12 | 2004-05-27 | Merck & Co., Inc. | Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer |
AU2003293155A1 (en) * | 2002-11-27 | 2004-06-23 | Elan Pharmaceutical, Inc. | Substituted ureas and carbamates |
GB0228410D0 (en) | 2002-12-05 | 2003-01-08 | Glaxo Group Ltd | Novel Compounds |
US7371853B2 (en) | 2003-01-07 | 2008-05-13 | Merck & Co., Inc. | Macrocyclic β-secretase inhibitors for the treatment of Alzheimer's disease |
JP2006520371A (ja) | 2003-03-14 | 2006-09-07 | メルク シャープ エンド ドーム リミテッド | 軽症の認識損傷の治療方法及びアルツハイマー病の予防又は遅延方法 |
GB0305918D0 (en) | 2003-03-14 | 2003-04-23 | Glaxo Group Ltd | Novel compounds |
TW200512195A (en) | 2003-04-21 | 2005-04-01 | Elan Pharm Inc | Benzamide 2-hydroxy-3-diaminoalkanes |
UY28279A1 (es) * | 2003-04-21 | 2004-11-30 | Pharmacia & Amp | Fenacilo 2 -hidroxi - 3 - diaminoalcanos |
GB0309221D0 (en) * | 2003-04-23 | 2003-06-04 | Glaxo Group Ltd | Novel compounds |
AU2003297826A1 (en) | 2003-06-16 | 2005-01-28 | Sunesis Pharmaceuticals, Inc | Aspartyl protease inhibitors |
WO2005004802A2 (fr) | 2003-06-30 | 2005-01-20 | Merck & Co., Inc. | Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer |
EP1643986A4 (fr) | 2003-07-01 | 2009-04-08 | Merck & Co Inc | Inhibiteurs de la beta-secretase de phenylcarboxylate destines au traitement de la maladie d'alzheimer |
GB0317491D0 (en) * | 2003-07-25 | 2003-08-27 | Novartis Ag | Organic compounds |
JP2007522129A (ja) * | 2004-01-21 | 2007-08-09 | エラン ファーマシューティカルズ,インコーポレイテッド | アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法 |
JP2007528403A (ja) * | 2004-03-09 | 2007-10-11 | エラン ファーマシューティカルズ,インコーポレイテッド | 二環式アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法 |
EP1751091A2 (fr) * | 2004-03-25 | 2007-02-14 | Elan Pharmaceuticals, Inc. | 1,3-diaminopropanes a substitution 2-amino- et 2-thio- |
-
2006
- 2006-11-13 WO PCT/US2006/044058 patent/WO2007061670A1/fr active Application Filing
- 2006-11-13 JP JP2008541258A patent/JP5274258B2/ja not_active Expired - Fee Related
- 2006-11-13 CA CA2629402A patent/CA2629402C/fr not_active Expired - Fee Related
- 2006-11-13 EP EP06837478A patent/EP1971598A1/fr not_active Withdrawn
- 2006-11-13 AU AU2006316620A patent/AU2006316620B2/en not_active Ceased
- 2006-11-20 PE PE2006001476A patent/PE20070645A1/es not_active Application Discontinuation
- 2006-11-21 AR ARP060105083A patent/AR057985A1/es unknown
- 2006-11-21 TW TW095143035A patent/TW200800966A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2009516684A (ja) | 2009-04-23 |
PE20070645A1 (es) | 2007-08-24 |
AU2006316620B2 (en) | 2011-03-03 |
AU2006316620A1 (en) | 2007-05-31 |
CA2629402A1 (fr) | 2007-05-31 |
EP1971598A1 (fr) | 2008-09-24 |
AR057985A1 (es) | 2008-01-09 |
TW200800966A (en) | 2008-01-01 |
WO2007061670A1 (fr) | 2007-05-31 |
JP5274258B2 (ja) | 2013-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7973047B2 (en) | Beta-Secretase modulators and methods of use | |
CA2629466C (fr) | Modulateurs de la beta-secretase et procedes d'utilisation de ceux-ci | |
AU2009291602B2 (en) | Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use | |
AU2008257145B2 (en) | Substituted hydroxyethyl amine compounds as Beta-secretase modulators and methods of use | |
AU2011207679B2 (en) | Amino heteroaryl compounds as beta-secretase modulators and methods of use | |
CA2629402C (fr) | Modulateurs de beta-secretase et procedes d'utilisation associes | |
CA2629462C (fr) | Modulateurs de beta-secretase et procedes d'utilisation | |
WO2009064418A1 (fr) | Composés d'hydroxyéthylamine substituée en tant que modulateurs de bêta-sécrétase et leurs procédés d'utilisation | |
US8552181B2 (en) | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | |
US7951838B2 (en) | Substituted spirocyclic chromanamine compounds as Beta-Secretase modulators and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20151113 |